Infliximab是一种嵌合型单克隆抗体,可靶向炎症性肠病(IBD)发病机制中起重要作用的促炎细胞因子-人肿瘤坏死因子-α(TNF-α)。Infliximab通过与巨噬细胞和T细胞表面的TNF-α结合而拮抗TNF-α的生物活性。Infliximab比大多数治疗IBD传统药物起效迅速,且药物不良反应较小。Infliximab可以有效治疗IBD,提高患者的生活质量。 Infliximab is a chimeric monoclonal antibody that targets the proinflammatory cytokine, human tumor necrosis factor-α (TNF-α), that plays an important role in the pathogenesis of inflammatory bowel disease (IBD). Infliximab antagonizes the biological activity of TNF-α by binding to TNF-α on the surface of macrophages and T cells. Infliximab works faster than most traditional IBD therapies and has less adverse drug reactions. Infliximab can effectively treat IBD and improve the quality of life of patients.